Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: A retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Barriere, Steven L ^a   Stryjewski, Martin E ^b   Corey, G R ^c   Genter, Fredric C ^a   Rubinstein, Ethan ^d  

^a THERAVANCE INC   (United States)

^b CEMIC   (Argentina)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Nosocomial pneumonia; Staphylococcus aureus; Trough levels; Vancomycin

Indexed keywords

TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; APACHE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HOSPITAL INFECTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; AGED; BLOOD; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84897965790     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-183     Document Type: Article

References (13)

1. DeRyke CA, Lodise TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005, 128(3):1414-1422. 10.1378/chest.128.3.1414, 16162737.
2. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416. American Thoracic Society; Infectious Diseases Society of America.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49(3):325-327. 10.1086/600877, 19569969.
4. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130(4):947-955. 10.1378/chest.130.4.947, 17035423.
5. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010, 9(1):9-14. 10.1517/14740330903413514, 20021290.
6. Kunkel M, Chastre JE, Kollef MH, Niederman MS, Shorr AF, Wunderink RG, McGee W, Olvey S, Reisman A, Baruch A. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus (abstract LB-49) 2010, Canada: Vancouver, BC, Infectious Diseases Society of America (IDSA) 48th Annual Meeting.
7. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29(6):1107-1115. 10.1016/j.clinthera.2007.06.014, 17692725.
8. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49(4):507-514. 10.1086/600884, 19586413.
9. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011, 52(8):969-974. 10.1093/cid/cir078, 21460308.
10. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME, for the ATTAIN Study Group Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011, 52(1):31-40. 10.1093/cid/ciq031, 3060890, 21148517, for the ATTAIN Study Group.
11. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011, 37(2):95-101. 10.1016/j.ijantimicag.2010.10.013, 21130609.
12. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011, 55(12):5475-5479. 10.1128/AAC.00168-11, 3232787, 21947388.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166(19):2138-2144. 10.1001/archinte.166.19.2138, 17060545.